EdwardJDrasbyDO

PubMed

• 239 citations
  A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit
  M. Flint Beal, David Oakes, Ira Shoulson, Claire Henchcliffe, Wendy R. Galpern
  JAMA Neurology. 2014-05-01
• 85 citations
  Haplotypes and Gene Expression Implicate the Mapt Region for Parkinson Disease: the GenePD Study
  J. E. Tobin, Jeanne C. Latourelle, Mark F. Lew, Christine Klein, Oksana Suchowersky
  Neurology. 2008-07-01
• 81 citations
  The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
  Jeanne C. Latourelle, Mei Sun, Mark F. Lew, Oksana Suchowersky, Christine Klein
  BMC Medicine. 2008-11-05

Journal Articles

• A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease.  
  C. Warren Olanow, M.D., Olivier Rascol, M.D., Ph.D., Robert Hauser, M.D., Paul D. Feigin, Ph.D., Joseph Jankovic, M.D., Anthony Lang, M.D., William Langston, M.D., E..., New England Journal of Medicine
• Detection of Cerebral Emboli with Transcranial Doppler Ultrasound.  
  Babikian,V.L., Schwarze, J.J., Drasby E.J, Klingelhofer, J, Journal of Vascular Technology

Lectures

• What is Parkinson’s Disease. 
  WCHS Television Program: “207” (Portland, Maine Local News & Events Forum)
• The Epidemiology, Pathophysiology, and Treatment of RLS. 
  Maine Restless Legs Syndrome Support Group (Monthly Meeting)
• Newly Approved Treatments for the Dementia of Parkinson’s Disease. 
  Novartis Sponsored Academic Lecture at Boston University Movement Disorders Conference
• Inhibition of MAO-B in the Treatment of Parkinson’s Disease. 
  Teva Pharmaceuticals sponsored luncheon program at Primecare Neurology, Biddeford, Maine
• Developments in the Treatment of Restless Legs Syndrome. 
  Maine Osteopathic Midwinter Conference, Marriott Sable Oaks, South Portland, Maine
• Research Advances in Continuous Dopaminergic Stimulation and Their Clinical Application. 
  Novartis Pharmaceutical sponsored Lecture, Slates Restaurant, Hallowell, Maine
• Diagnosis and Treatment of Restless Legs Syndrome, and Other Parasomnias. 
  Galaxo Smith Kline: Pharmaceutical Sponsored Lecture, Eastern Maine Neurology Associates. Bangor
• Addressing the Motor and Non-Motor Complications of Parkinson’s Disease. 
  Novartis Pharmaceutical sponsored lecture, On the Marsh Inn, Kennebunk, Maine
• New Advances in the Treatment of Parkinson’s Disease. 
  Falmouth, Maine: Parkinson’s Disease Support Group
• 9TH International Congress of Movement Disorders: A four day Symposium dedicated to Movement Disorders. 
  New Orleans, Louisiana
• New Advances Parkinson’s Disease. 
  WCHS Television Program: “207” (Portland, Maine Local News & Events Forum)
• A review of the Focal Dystonias, and utilization of DBS Technology in the Treatment of Primary Torsion Dystonia (DYT-1). 
  Neurology Grand Rounds, Maine Medical Center; Portland, Maine
• Overview of Parkinson’s Disease: Pathophysiology, Diagnosis and Treatment. 
  Down East Association of Physicians Assistants (DEAPA)
• Clinical Progression of Parkinson’s Disease and the Role of Levodopa Treatment. 
  York Neurology Group, York Maine
• What is Parkinson’s Disease? 
  New England Society of Electrodiagnostic Technicians, Wynwood Hotel, Portsmouth, New Hampshire
• An Overview of Parkinson’s Disease, and Current Research. 
  Geriatric Medicine Grand Rounds, Maine Medical Center; Portland, Maine
• The Atypical Features of Parkinson’s Disease and their Treatment. 
  Southern Maine Parkinson’s Disease Support Group, Southern Maine Medical Center, Saco, Maine
• Initiation of Levodopa Therapy in Parkinson’s Disease: Early vs. Late L-Dopa. 
  Novartis Pharmaceutical sponsored lecture, White Barn Inn, Kennebunkport, Maine
• Deep Brain Stimulation Surgery in the Management of Parkinson’s Disease. 
  Falmouth, Maine Parkinson’s Disease Support Group: Two hour interactive lecture
• Symposium on Focal Dystonias,” followed by Q&A, and interview with a primary torsion dystonia patient, who had recently had DBS implantation. 
  Annual meeting of Maine Dystonia Society, Dana Center at Maine Medical Center, Portland, Maine
• : Two hour interactive question and answer exchange with 40-50 Parkinson’s Disease patients. 
  The Parkinson’s Program, Pine Tree Society, Scarborough Maine
• New Concepts for the Treatment of Parkinson’s Disease. 
  Novartis Pharmaceutical sponsored lecture, White Barn Inn, Kenebunkport, Maine
• Current Research in Dystonia. 
  Dystonia Medical Research Foundation sponsored Dystonia Awareness Day, Dana Center
• Non-Motor Symptoms of Parkinson’s Disease. 
  Geriatric Grand Rounds
• Living with Parkinson’s Disease: How Motor and Non-Motor Symptoms Define the Course of Parkinson’s Disease. 
  Portland, Maine, 2002; Bangor, Maine
• Join now to see all

Other

• Polymorphisms and Expression in SIRT3 are associated with Parkinson disease: the GenePD Study. 
  Nagle MW, BA1; Latourelle JC, DSc2; Lew MF, MD4; Klein C, MD5; Golbe LI, MD6; Mark MH, MD6; Growdon JH, MD7; Wooten GF, MD9; Watts RL, MD10; Litvan I, MD18; Drasby E...
• Alpha-synuclein and familial Parkinson's disease. 
  Nathan Pankratz, PhD, William C. Nichols, PhD, Veronika E. Elsaesser, BS, Michael W. Pauciulo, MBA, Diane K. Marek, BS, Cheryl A. Halter, MS, Joanne Wojcieszek, MD, ...
• Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. 
  N. Pankratz, PhD, D. K. Kissell, BS, M. W. Pauciulo, MBA, C. A. Halter, MS, A. Rudolph, PhD, R. F. Pfeiffer, MD, K. S. Marder, MD, T. Foroud, PhD, W. C. Nichols, PhD ...
• Genomewide association study for susceptibility genes contributing to familial Parkinson disease. 
  Nathan Pankratz, Jemma B. Wilk, Jeanne C. Latourelle, Anita L. DeStefano, Cheryl Halter, Elizabeth W. Pugh, Kimberly F. Doheny, James F. Gusella, William C. Nichols,...
• Replication of Association between ELAVL4 and Parkinson Disease; The GenePD Study. 
  L.I. Golbe, MD, M.H. Mark, MD, J.H. Growdon, MD, G.F. Wooten, MD, R. Watts, MD, E. Drasby, S. Isaacson, et al
• Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study. 
  J.E. Tobin, PhD, E. Drasby, DO, R.H. Myers et al
• Treating Cognitive Dysfunction in Parkinson’s Disease: A cognitive neuroscience-based approach to attenuating deficits of selective attention. 
  Shawn Ell, University of Maine; Edward Drasby, University of New England
• Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. 
  Robert A. Hauser, MD 1 *, Laurence Salin, MD 2, Nolwenn Juhel, MD 2, Victor L. Konyago, MD 3, NS 2330 Monotherapy PD Study Group (Edward J. Drasby, et al.)
• The Effect of GSTP1 Polymorphism on Onset Age of Parkinson Disease Is Modified by Occupational Exposure to Herbicides in Males: The GenePD Study. 
  Wilk, Gemma, et al… E. Drasby, Myers, RH, Golbe, LI
• Type-1 Protein Phosphatase Inhibitor 4 (PPP1R2P9) on Xp11.4-11.3 is associated with Familial and Idiopathic Parkinson’s disease: The GenePD Study. 
  Gang Xu, et al… Edward Drasby, Richard H. Myers
• Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. 
  N E Maher, L I Golbe, et al…, E Drasby, S Isaacson, P Vieregge, P Pramstaller, C Klein, J Hubble, C Reider, J Growdon, R Watts, E Montgomery, K Baker, C Singer, M St...
• 3D Computer Kinematic System Demonstrates Cranial Bone Movement About the Cranial Sutures. 
  Lewandoski, M.A., Drasby, E.J., Zanakis, M.F, American Osteopathic Academy Abstract
  Las Vegas, Nevada
• Design and Development of a ‘Dynamic Skull Model’ as a Training Tool for Palpation of the Cranial Rhythmic Impulse. 
  Lewandoski, M.A., Drasby, E.J., Morgan, M., Zanakis, M.F, AOA Abstract
  Las Vegas, Nevada
• Objective measurement of the CRI with manipulation and palpation of the sacrum. 
  Zanakis, M.F., DiMeo, J., Madonna, S., Morgan, M., Drasby, E, American Osteopathic Academy Abstract
  Las Vegas, Nevada
• Secondary Parkinsonism” Chapter on internet medical informational website. 
  Feldman, RG, Drasby EJ
• Join now to see all